Rivaroxaban (Xarelto, Janssen/Bayer) is a direct factor Xa inhibitor used orally in the prevention of thromboembolism in the setting of atrial fibrillation or atrial flutter. Rivaroxaban is also used for deep venous thrombosis prophylaxis after orthopedic surgery.

Rivaroxaban is renally cleared and the dose must be reduced in the setting of renal insufficiency.